Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome

Circulation

Volumn 93, Issue 8, 1996, Pages 1579-1587

  Hojnik, Maja ^a   George, Jacob ^a   Ziporen, Lea ^a   Shoenfeld, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

antibodies; pathology; rheumatic heart disease; valves

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BACTERIAL ENDOCARDITIS; CLINICAL FEATURE; CLINICAL TRIAL; ENDOCARDITIS; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

EID: 0029919622     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.8.1579     Document Type: Review

References (110)

1. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986;13:486-489.
2. Harris EN. A reassessment of the antiphospholipid syndrome. J Rheumatol. 1990;17:733-735.
3. Briley DP, Coull BM, Goodnight SH. Neurological disease associated with antiphospholipid antibodies. Ann Neurol. 1989;25; 221-227.
4. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990;40:1181-1189.
5. Rote NS. Antiphospholipid antibodies and disorders of pregnancy. J Clin Immunoassay. 1990;13:34-42.
6. Asherson RA, Hughes GRV. The expanding spectrum of Libman Sacks endocarditis: the role of antiphospholipid antibodies. Clin Exp Rheumatol. 1989;7:225-228.
7. Grob JJ, Bonerandi JJ. Thrombotic skin disease as a marker of the anticardiolipin syndrome. J Am Acad Dermatol. 1989;20: 1063-1069.
8. Asherson RA, Cervera R. 'Primary,' 'secondary' and other variants of the antiphospholipid syndrome. Lupus. 1994;3:293-298.
9. Santiago MB, Cossermelli W, Tuma MF, Pinto MN, Oliveira RM. Anticardiolipin antibodies in patients with infectious diseases. Clin Rheumatol. 1989;1:23-28.
10. 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus. 1994;3:515-521.
11. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet. 1993;342:341-344.
12. Triplett DA. Assays for detection of antiphospholipid antibodies. Lupus. 1994;3:281-287.
13. Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74: 1-9. Annotation.
14. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
15. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544-1547.
16. Sammaritano LR, Lockshin MD, Gharavi AE. Antiphospholipid antibodies differ in aPL cofactor requirement. Lupus. 1992;1: 83-90.
17. 2-glycoprotein I. J Clin Invest. 1992;90: 1100-1104.
18. 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost. 1992;68: 297-300.
19. 2-glycoprotein I. Thromb Haemost. 1992;67:499-502.
20. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994;179:457-462.
21. 2-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol. 1995;154:954-960.
22. 2-glycoprotein I contains a phospholipid binding site (cys281-cys288) and a region recognized by anticardiolipin antibodies. J Immunol. 1994;152: 653-659.
23. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's are not directed to phospholipids only, but to a complex of lipid bound human prothrombin. Thromb Haemost. 1991;66:629-632.
24. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, deGroot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81:2618-2625.
25. 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994;83: 2878-2892.
26. Fleck RA, Rapaport SI, Rao LVM. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988;72:512-519.
27. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid' autoantibodies. Blood. 1994;84:2854-2867.
28. Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun. 1988;155: 1001-1007.
29. McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol. 1989;73:506-513.
30. Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss and thrombocytopenia: predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986;146:2153-2156.
31. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders - prevalence and clinical significance. Ann Intern Med. 1990;112:682-698.
32. Reyes H, Dearing L, Shoenfeld Y, Peter JB. Antiphospholipid antibodies: a critique of their heterogeneity and hegemony. Semin Thromb Hemost. 1994;20:89-100.
33. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T. Anticardiolipin antibodies in NZWXBXSB F1 mice: a model of antiphospholipid syndrome. J Immunol. 1992;149:1063-1068.
34. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A. 1991;88:3069-3073.
35. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest. 1992;89:1558-1563.
36. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 1994;71:670-674.
37. Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood. 1994;83:2532-2540.
38. Shibata S, Sasaki T, Harpel P, Fillit H. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol. 1994; 70:114-123.
39. Sammaritano LR, Gharavi AE, Soberano C, Levy RA, Lockshin MD. Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein. J Clin Immunol. 1992;12:27-35.
40. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923-925.
41. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-27.
42. Witztum JL. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J. 1993;69(suppl):S12-S18.
43. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701-737.
44. Baehr G, Klemperer K, Schifrin A. A diffuse disease of the peripheral circulation usually associated with lupus erythematosus and endocarditis. Trans Assoc Am Physicians. 1935;50:139-155.
45. Gross L. The cardiac lesion in Libman-Sacks disease with a consideration of its relationship to acute diffuse lupus erythematosus. Am J Pathol. 1940;16:375-408.
46. Shearn MA. The heart in systemic lupus erythematosus: a review. Am Heart J. 1959;58:452-466.
47. Bridgen W, Bywaters EG, Lessof MH, Ross IP. The heart in systemic lupus erythematosus. Br Heart J. 1960;22:1-16.
48. Kong TQ, Kellum RE, Haserick JR. Clinical diagnosis of cardiac involvement in systemic lupus erythematosus: a correlation of clinical and autopsy findings in thirty patients. Circulation. 1962; 26:7-11.
49. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med. 1975;58:243-264.
50. Ansari A, Larson PH, Bates HD. Cardiovascular manifestations of systemic lupus erythematosus: current perspective. Prog Cardiovasc Dis. 1985;27:421-434.
51. Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum. 1987;17:126-141.
52. Klinkhoff AV, Thompson CR, Reid GD, Tomlinson CW. M-mode and two-dimensional echocardiographic abnormalities in systemic lupus erythematosus. JAMA. 1985;253:3273-3277.
53. Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med. 1988;319:817-823.
54. Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med. 1988;85:645-650.
55. D'Alton JG, Preston DN, Bormanis J, Green MS, Kraag GR. Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis. Stroke. 1985;16:512-514.
56. Anderson D, Bell D, Lodge R, Grant E. Recurrent cerebral ischemia and mitral valve vegetation in a patient with antiphospholipid antibodies. J Rheumatol. 1987;14:839-841.
57. Ford PM, Ford SE, Lillicrap DP. Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus. J Rheumatol. 1988;15:597-600.
58. Asherson RA, Lubbe WF. Cerebral and valve lesions in SLE: association with antiphospholipid antibodies. J Rheumatol. 1988; 15:539-543.
59. Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med. 1989;86:407-412.
60. Khamashta MA, Gil A, Asherson RA, Vazquez JJ, Hughes GRV. Antiphospholipid antibodies, valvular heart disease, and systemic lupus erythematosus. Am J Med. 1989;86:633-634. Letter.
61. Straaton KV, Chatham WW, Smith SH, Koopman WJ. Valvular heart disease in systemic lupus erythematosus. N Engl J Med. 1989;320:740. Letter.
62. Galve E, Ordi J, Candell-Riera J, Permanyer-Miralda G, Vilardell M, Soler-Soler J. Valvular heart disease in systemic lupus erythematosus. N Engl J Med. 1989;320:740-741. Letter.
63. Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, Vazquez JJ, Pare C, Ingelmo M, Oliver J, Hughes GRV. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990;335: 1541-1544.
64. Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus: association with raised anticardiolipin antibodies. Circulation. 1990;82:369-375.
65. Cervera R, Font J, Pare C, Azqueta M, Perez-Villa F, Lopez-Soto A, Ingelmo M. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis. 1992;51:156-159.
66. Jouhikainen T, Pohjola-Sintonen S, Stephansson E. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus. 1994;3:167-172.
67. Roldan CA, Shively BK, Lau CC, Gurule FT, Smith EA, Crawford MH. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol. 1992;20:1127-1134.
68. Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J. 1993;125: 1123-1129.
69. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, Vilardell M, Hughes GRV. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med. 1994;96:3-9.
70. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med. 1990;89: 411-419.
71. Giunta A, Picillo U, Maione S, Migliaresi S, Valentini G, Arnese M, Losardo L, Marone G, Tirri G, Condorelli M. Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. Acta Cardiol. 1993;48:183-197.
72. Brenner B, Blumenfeld Z, Markiewicz W, Reisner SA. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol. 1991;18:931-936.
73. Cervera R, Khamashta A, Font J, Reyes PA, Vianna JL, Lopez-Soto A, Amigo MC, Asherson RA, Azqueta M, Pare C, Vargas J, Romero A, Ingelmo M, Hughes GRV. High prevalence of significant heart valve lesions in patients with the primary antiphospholipid syndrome. Lupus. 1991;1:43-47.
74. Galve E, Ordi J, Barquinero J, Evangelista A, Vilardell M, Soler-Soler J. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med. 1992;116:293-298.
75. Barbut D, Borer JS, Gharavi A, Wallerson D, Devereux RB, Supino P, Suite NDA. Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or both, and possible relation to cerebral ischemic events. Am J Cardiol. 1992;70: 901-905.
76. Pope JM, Canny CLB, Bell DA. Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med. 1991;90:299-309.
77. Ford SE, Lillicrap D, Brunet D, Ford P. Thrombotic endocarditis and lupus anticoagulant. Arch Pathol Lab Med. 1989;113:350-353.
78. Murphy JJ, Leach IH. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J. 1989;62:61-64.
79. Ford SE, Charette EJP, Knight J, Pym J, Ford P. A possible role for antiphospholipid antibodies in acquired cardiac valve deformity. J Rheumatol. 1990;17:1499-1503.
80. O'Hickey S, Skinner C, Beattie J. Life-threatening ventricular thrombosis in association with phospholipid antibodies. Br Heart J. 1993;70:279-281.
81. Alvarez-Blanco A, Egurbide-Arberas MV, Aguirre-Errasti C. Severe valvular heart disease in a patient with primary antiphospholipid syndrome. Lupus. 1994;3:433-434.
82. Nickele GA, Foster PA, Kenny D. Primary antiphospholipid syndrome and mitral valve thrombosis. Am Heart J. 1994;128: 1245-1247.
83. Barbut D, Borer J, Wallerson D, Ameisen O, Lockshin M. Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. Cardiology. 1991;79:99-109.
84. Jafar MZ, Chester MM, Gorcsan J. Transesophageal echocardiographic detection of multiple mitral valve masses in primary antiphospholipid syndrome with stroke. Am Heart J. 1994;127: 445-446.
85. Fulham MJ, Gatenby P, Tuck RR. Focal cerebral ischemia and antiphospholipid antibodies: a case for cardiac embolism. Acta Neurol Scand. 1994;90:417-423.
86. Fox IS, Spence AM, Wheelis RF, Healey LA. Cerebral embolism in Libman-Sacks endocarditis. Neurology. 1980;30:487-491.
87. Gorenck PB, Rusinowitz MD, Tiku M, McDonald LW, Robbins L. Embolic stroke complicating systemic lupus erythematosus. Arch Neurol 1985;42:813-815.
88. The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke. 1990;21:1268-1273.
89. Lehman TJA, Palmeri ST, Hastings C, Klippel JH, Plotz PH. Bacterial endocarditis complicating systemic lupus erythematosus. J Rheumatol. 1983;10:655-658.
90. Asherson RA, Gibson DG, Evans DW, Baguley E, Hughes GRV. Diagnostic and therapeutic problems in two patients with antiphospholipid antibodies, heart valve lesions, and transient ischaemic attacks. Ann Rheum Dis. 1988;47:947-953.
91. Font J, Cervera R, Pare C, Lopez-Soto A, Pallares L, Azqueta M, Khamashta MA. Non-infective verrucous endocarditis in a patient with 'primary' antiphospholipid syndrome. Br J Rheumatol. 1991; 30:305-307.
92. Asherson RA, Cervera R. Antiphospholipid antibodies and the heart: lessons and pitfalls for the cardiologist. Circulation. 1991;84: 920-922. Editorial.
93. McGrae KR, de Michelle A, Samuels P, Roth D, Kuo A, Meg QH, Rauch J, Cines DA. Detection of endothelial cell reactive immunoglobulin in patients with antiphospholipid antibodies. Br J Haematol. 1991;79:595-605.
94. Cervera R, Khamashta MA, Font J, Ramirez J, Cruz D, Montalban J, Lopez-Soto A, Asherson RA, Ingelmo M, Hughes GRVH. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity. 1991;11:1-6.
95. Hasselaar P, Derksen RHWM, Blokzijl L, de Groot PG. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost. 1990;63:169-173.
96. Galli M, Bevers EM. Inhibition of phospholipid-dependent coagulation reactions by 'antiphospholipid antibodies': possible modes of action. Lupus. 1994;3:223-228.
97. 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995;13:179-185.
98. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol. 1994;153:1328-1332.
99. Shapiro RF, Gamble CN, Wiesner KB, Castles JJ, Wolf AW, Hurley EJ, Salel AF. Immunopathogenesis of Libman-Sacks endocarditis: assessment by light and immunofluorescent microscopy in two patients. Ann Rheum Dis. 1977;36:508-516.
100. Bidani AK, Roberts JL, Schwartz MM, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med. 1980;69:849-858.
101. Ziporen L, Goldberg I, Kopolovic Y, Arad M, Sandbank Y, Ordi-Rose J, Vilardell-Tarress M, De Torres I, Adler Y, Weinberger A, Asherson RA, Shoenfeld Y. Libman Sacks endocarditis: the possible pathogenic role of anti-cardiolipin antibodies deposited at the valve subendothelium. Lupus. 1995;4(suppl 2):100. Abstract.
102. Ford SE, Kennedy L, Ford PM. Clinicopathologic correlations of antiphospholipid antibodies: an autopsy study. Arch Pathol Lab Med. 1994;118:491-495.
103. Lie JT. Vasculitis in the antiphospholipid syndrome: culprit or consort? J Rheumatol. 1994;21:397-398. Editorial.
104. Lockshin MD. Answers to the antiphospholipid syndrome? N Engl J Med. 1995;332:1025-1027. Editorial.
105. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332: 993-997.
106. Derksen RHWM, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis. 1993;52:689-692.
107. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303-308.
108. Brey RL. Stroke prevention in patients with antiphospholipid antibodies. Lupus. 1994;3:299-302.
109. Shoenfeld Y, Blank M. Effect of long-acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome. Lupus. 1994;3:397-400.
110. Fishman P, Falach-Vaknine E, Zigelman R, Bakimer R, Sredni B, Djaldetti M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest. 1993;91:1834-1837.